Stem definition | Drug id | CAS RN |
---|---|---|
antihyperlipidaemic substances, HMG CoA reductase inhibitors | 1229 | 93957-54-1 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.62 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 24 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.42 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1993 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 144.65 | 14.68 | 138 | 8736 | 131887 | 56151306 |
Rhabdomyolysis | 121.12 | 14.68 | 77 | 8797 | 40581 | 56242612 |
Blood creatine phosphokinase increased | 117.26 | 14.68 | 66 | 8808 | 27886 | 56255307 |
Limb reduction defect | 101.75 | 14.68 | 21 | 8853 | 366 | 56282827 |
Dysmorphism | 73.72 | 14.68 | 23 | 8851 | 2190 | 56281003 |
Cleft palate | 72.51 | 14.68 | 19 | 8855 | 966 | 56282227 |
Gamma-glutamyltransferase increased | 66.65 | 14.68 | 48 | 8826 | 30957 | 56252236 |
Atrial septal defect | 65.66 | 14.68 | 28 | 8846 | 6478 | 56276715 |
Talipes | 65.34 | 14.68 | 19 | 8855 | 1423 | 56281770 |
Patent ductus arteriosus | 60.66 | 14.68 | 23 | 8851 | 3928 | 56279265 |
Limb hypoplasia congenital | 59.52 | 14.68 | 12 | 8862 | 185 | 56283008 |
Antinuclear antibody negative | 58.42 | 14.68 | 12 | 8862 | 204 | 56282989 |
Congenital oral malformation | 53.72 | 14.68 | 11 | 8863 | 184 | 56283009 |
Coombs positive haemolytic anaemia | 52.86 | 14.68 | 12 | 8862 | 332 | 56282861 |
Alanine aminotransferase increased | 50.78 | 14.68 | 68 | 8806 | 93594 | 56189599 |
Drug ineffective | 50.23 | 14.68 | 43 | 8831 | 918946 | 55364247 |
Retrognathia | 49.84 | 14.68 | 12 | 8862 | 431 | 56282762 |
Aspartate aminotransferase increased | 49.48 | 14.68 | 63 | 8811 | 82539 | 56200654 |
Herpes simplex reactivation | 48.39 | 14.68 | 12 | 8862 | 488 | 56282705 |
Developmental hip dysplasia | 45.24 | 14.68 | 14 | 8860 | 1297 | 56281896 |
Myopathy | 43.38 | 14.68 | 24 | 8850 | 9788 | 56273405 |
Acute kidney injury | 41.09 | 14.68 | 106 | 8768 | 240657 | 56042536 |
Antiphospholipid syndrome | 38.35 | 14.68 | 13 | 8861 | 1608 | 56281585 |
Gastritis haemorrhagic | 36.02 | 14.68 | 12 | 8862 | 1407 | 56281786 |
Neck deformity | 35.45 | 14.68 | 13 | 8861 | 2022 | 56281171 |
Rheumatoid arthritis | 34.34 | 14.68 | 9 | 8865 | 382595 | 55900598 |
Lactic acidosis | 33.11 | 14.68 | 34 | 8840 | 35312 | 56247881 |
Pancreatitis acute | 32.73 | 14.68 | 29 | 8845 | 25095 | 56258098 |
Jaundice | 32.60 | 14.68 | 30 | 8844 | 27264 | 56255929 |
Complex regional pain syndrome | 31.30 | 14.68 | 12 | 8862 | 2111 | 56281082 |
Anxiety disorder | 30.66 | 14.68 | 14 | 8860 | 3806 | 56279387 |
Premature baby | 28.74 | 14.68 | 24 | 8850 | 19181 | 56264012 |
Interstitial lung disease | 28.74 | 14.68 | 40 | 8834 | 57023 | 56226170 |
Off label use | 27.92 | 14.68 | 28 | 8846 | 556152 | 55727041 |
Blood alkaline phosphatase increased | 27.01 | 14.68 | 32 | 8842 | 38913 | 56244280 |
Aplasia | 26.99 | 14.68 | 13 | 8861 | 3983 | 56279210 |
Muscle spasms | 26.03 | 14.68 | 63 | 8811 | 137308 | 56145885 |
Hyperlipidaemia | 25.80 | 14.68 | 22 | 8852 | 18087 | 56265106 |
Drug interaction | 25.68 | 14.68 | 82 | 8792 | 209673 | 56073520 |
Muscular weakness | 25.50 | 14.68 | 53 | 8821 | 104399 | 56178794 |
Alopecia | 24.31 | 14.68 | 8 | 8866 | 293450 | 55989743 |
Peripheral swelling | 24.17 | 14.68 | 4 | 8870 | 234722 | 56048471 |
Coronary artery disease | 22.51 | 14.68 | 26 | 8848 | 30770 | 56252423 |
Joint swelling | 22.14 | 14.68 | 9 | 8865 | 289791 | 55993402 |
Pulmonary artery stenosis | 21.23 | 14.68 | 5 | 8869 | 163 | 56283030 |
Blood creatinine increased | 21.12 | 14.68 | 42 | 8832 | 80149 | 56203044 |
Hypernatraemia | 20.84 | 14.68 | 13 | 8861 | 6607 | 56276586 |
Neonatal seizure | 20.71 | 14.68 | 6 | 8868 | 443 | 56282750 |
Chromaturia | 20.58 | 14.68 | 18 | 8856 | 15307 | 56267886 |
Immunosuppressant drug level increased | 20.22 | 14.68 | 10 | 8864 | 3243 | 56279950 |
Haematoma | 20.07 | 14.68 | 25 | 8849 | 31994 | 56251199 |
Erysipelas | 19.82 | 14.68 | 13 | 8861 | 7200 | 56275993 |
Cerebrovascular accident | 19.30 | 14.68 | 46 | 8828 | 99224 | 56183969 |
Otospondylomegaepiphyseal dysplasia | 19.26 | 14.68 | 4 | 8870 | 72 | 56283121 |
Angiosclerosis | 19.11 | 14.68 | 3 | 8871 | 9 | 56283184 |
Cholestasis | 18.47 | 14.68 | 22 | 8852 | 26891 | 56256302 |
Blood urea increased | 18.46 | 14.68 | 21 | 8853 | 24452 | 56258741 |
Pleuritic pain | 17.66 | 14.68 | 12 | 8862 | 7045 | 56276148 |
Osteonecrosis | 17.64 | 14.68 | 20 | 8854 | 23195 | 56259998 |
Product use issue | 17.40 | 14.68 | 4 | 8870 | 186037 | 56097156 |
Therapeutic product effect decreased | 17.19 | 14.68 | 3 | 8871 | 169449 | 56113744 |
Hepatic cytolysis | 17.09 | 14.68 | 14 | 8860 | 10892 | 56272301 |
Bradycardia neonatal | 16.90 | 14.68 | 6 | 8868 | 851 | 56282342 |
Cerebral ischaemia | 16.69 | 14.68 | 11 | 8863 | 6139 | 56277054 |
Sterile pyuria | 16.68 | 14.68 | 3 | 8871 | 24 | 56283169 |
Nephroangiosclerosis | 16.66 | 14.68 | 4 | 8870 | 142 | 56283051 |
Hypothyroidism | 16.63 | 14.68 | 25 | 8849 | 38171 | 56245022 |
Ocular myasthenia | 16.60 | 14.68 | 4 | 8870 | 144 | 56283049 |
Synovitis | 16.05 | 14.68 | 3 | 8871 | 161302 | 56121891 |
Foetal exposure during pregnancy | 15.97 | 14.68 | 23 | 8851 | 33800 | 56249393 |
Hepatic function abnormal | 15.59 | 14.68 | 23 | 8851 | 34535 | 56248658 |
Fasciitis | 15.31 | 14.68 | 5 | 8869 | 551 | 56282642 |
Amyotrophic lateral sclerosis | 15.29 | 14.68 | 6 | 8868 | 1122 | 56282071 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 275.69 | 16.09 | 205 | 8857 | 77053 | 31611229 |
Blood creatine phosphokinase increased | 159.77 | 16.09 | 116 | 8946 | 41858 | 31646424 |
Rectal prolapse | 80.90 | 16.09 | 20 | 9042 | 434 | 31687848 |
Intraductal papillary mucinous neoplasm | 77.83 | 16.09 | 20 | 9042 | 510 | 31687772 |
Myopathy | 75.88 | 16.09 | 44 | 9018 | 10808 | 31677474 |
Renal cyst haemorrhage | 75.80 | 16.09 | 20 | 9042 | 567 | 31687715 |
Muscle rupture | 71.86 | 16.09 | 26 | 9036 | 2137 | 31686145 |
SARS-CoV-2 antibody test positive | 59.08 | 16.09 | 15 | 9047 | 364 | 31687918 |
Vena cava injury | 57.34 | 16.09 | 14 | 9048 | 288 | 31687994 |
Abdominal wall haemorrhage | 56.69 | 16.09 | 15 | 9047 | 430 | 31687852 |
Carotid arteriosclerosis | 54.21 | 16.09 | 20 | 9042 | 1737 | 31686545 |
Vascular anastomotic haemorrhage | 53.78 | 16.09 | 13 | 9049 | 256 | 31688026 |
Delayed graft function | 53.75 | 16.09 | 21 | 9041 | 2134 | 31686148 |
Aortic dilatation | 52.99 | 16.09 | 18 | 9044 | 1227 | 31687055 |
Diverticulum intestinal | 52.62 | 16.09 | 24 | 9038 | 3579 | 31684703 |
Off label use | 50.91 | 16.09 | 18 | 9044 | 347256 | 31341026 |
Perineal cyst | 49.37 | 16.09 | 12 | 9050 | 242 | 31688040 |
Gamma-glutamyltransferase increased | 48.13 | 16.09 | 49 | 9013 | 27776 | 31660506 |
Renal artery stenosis | 46.89 | 16.09 | 19 | 9043 | 2123 | 31686159 |
Vascular compression | 45.42 | 16.09 | 12 | 9050 | 342 | 31687940 |
Mean cell volume increased | 44.70 | 16.09 | 20 | 9042 | 2852 | 31685430 |
Restless legs syndrome | 42.74 | 16.09 | 27 | 9035 | 7729 | 31680553 |
Hyperparathyroidism secondary | 42.34 | 16.09 | 16 | 9046 | 1485 | 31686797 |
Amyotrophic lateral sclerosis | 40.83 | 16.09 | 14 | 9048 | 982 | 31687300 |
Aortic arteriosclerosis | 40.68 | 16.09 | 21 | 9041 | 4102 | 31684180 |
Actinic keratosis | 40.42 | 16.09 | 21 | 9041 | 4158 | 31684124 |
Rhabdomyolysis | 38.71 | 16.09 | 67 | 8995 | 63514 | 31624768 |
Hepatosplenomegaly | 38.67 | 16.09 | 20 | 9042 | 3923 | 31684359 |
Spinal stenosis | 37.90 | 16.09 | 21 | 9041 | 4727 | 31683555 |
Glycosylated haemoglobin increased | 37.80 | 16.09 | 28 | 9034 | 10372 | 31677910 |
Intervertebral disc space narrowing | 37.56 | 16.09 | 13 | 9049 | 938 | 31687344 |
Vertigo | 36.94 | 16.09 | 39 | 9023 | 23046 | 31665236 |
Left ventricular hypertrophy | 34.21 | 16.09 | 23 | 9039 | 7309 | 31680973 |
Haemorrhoids | 33.48 | 16.09 | 28 | 9034 | 12354 | 31675928 |
Spinal osteoarthritis | 32.95 | 16.09 | 22 | 9040 | 6913 | 31681369 |
Arteriosclerosis | 32.59 | 16.09 | 26 | 9036 | 10741 | 31677541 |
Myocardial infarction | 32.44 | 16.09 | 88 | 8974 | 113366 | 31574916 |
Dysuria | 31.89 | 16.09 | 37 | 9025 | 24257 | 31664025 |
Vestibular neuronitis | 31.32 | 16.09 | 8 | 9054 | 199 | 31688083 |
Swelling of eyelid | 30.63 | 16.09 | 11 | 9051 | 884 | 31687398 |
Blood 25-hydroxycholecalciferol decreased | 30.45 | 16.09 | 8 | 9054 | 223 | 31688059 |
Face oedema | 28.69 | 16.09 | 24 | 9038 | 10592 | 31677690 |
Toxicity to various agents | 27.22 | 16.09 | 9 | 9053 | 181478 | 31506804 |
Tendon rupture | 27.00 | 16.09 | 19 | 9043 | 6500 | 31681782 |
Aspartate aminotransferase increased | 26.94 | 16.09 | 57 | 9005 | 62662 | 31625620 |
General physical health deterioration | 26.63 | 16.09 | 82 | 8980 | 113353 | 31574929 |
Blood potassium increased | 26.48 | 16.09 | 27 | 9035 | 15318 | 31672964 |
Death | 26.41 | 16.09 | 39 | 9023 | 360530 | 31327752 |
Benign prostatic hyperplasia | 26.19 | 16.09 | 25 | 9037 | 13100 | 31675182 |
Angina pectoris | 26.05 | 16.09 | 37 | 9025 | 29604 | 31658678 |
Vitamin D decreased | 25.63 | 16.09 | 14 | 9048 | 3063 | 31685219 |
Activated partial thromboplastin time prolonged | 25.18 | 16.09 | 20 | 9042 | 8205 | 31680077 |
Generalised oedema | 25.05 | 16.09 | 23 | 9039 | 11478 | 31676804 |
Febrile bone marrow aplasia | 23.85 | 16.09 | 19 | 9043 | 7827 | 31680455 |
Fear | 23.80 | 16.09 | 21 | 9041 | 9953 | 31678329 |
Coronary artery disease | 23.50 | 16.09 | 45 | 9017 | 46042 | 31642240 |
Hepatic steatosis | 23.46 | 16.09 | 26 | 9036 | 16213 | 31672069 |
Squamous cell carcinoma of skin | 23.44 | 16.09 | 21 | 9041 | 10153 | 31678129 |
Complications of transplanted kidney | 21.28 | 16.09 | 14 | 9048 | 4291 | 31683991 |
Presyncope | 20.44 | 16.09 | 25 | 9037 | 17303 | 31670979 |
Product dose omission issue | 20.30 | 16.09 | 3 | 9059 | 105583 | 31582699 |
Perioral dermatitis | 19.86 | 16.09 | 5 | 9057 | 117 | 31688165 |
Large intestine polyp | 19.29 | 16.09 | 16 | 9046 | 6976 | 31681306 |
Seizure | 18.80 | 16.09 | 3 | 9059 | 99765 | 31588517 |
Congenital inguinal hernia | 18.40 | 16.09 | 5 | 9057 | 159 | 31688123 |
Aortic valve incompetence | 18.10 | 16.09 | 14 | 9048 | 5527 | 31682755 |
Chronic kidney disease | 18.05 | 16.09 | 36 | 9026 | 37939 | 31650343 |
Myocardial ischaemia | 17.99 | 16.09 | 23 | 9039 | 16644 | 31671638 |
Funguria | 17.83 | 16.09 | 4 | 9058 | 56 | 31688226 |
Renal cyst | 16.73 | 16.09 | 16 | 9046 | 8400 | 31679882 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 324.85 | 13.71 | 269 | 14003 | 167623 | 70746549 |
Blood creatine phosphokinase increased | 245.37 | 13.71 | 153 | 14119 | 61110 | 70853062 |
Rhabdomyolysis | 113.64 | 13.71 | 117 | 14155 | 95643 | 70818529 |
Myopathy | 110.29 | 13.71 | 60 | 14212 | 18552 | 70895620 |
Gamma-glutamyltransferase increased | 84.99 | 13.71 | 75 | 14197 | 50610 | 70863562 |
Renal cyst haemorrhage | 80.93 | 13.71 | 20 | 14252 | 624 | 70913548 |
Intraductal papillary mucinous neoplasm | 76.82 | 13.71 | 20 | 14252 | 772 | 70913400 |
Off label use | 75.13 | 13.71 | 28 | 14244 | 743032 | 70171140 |
SARS-CoV-2 antibody test positive | 64.27 | 13.71 | 15 | 14257 | 365 | 70913807 |
Aspartate aminotransferase increased | 63.57 | 13.71 | 101 | 14171 | 126877 | 70787295 |
Vena cava injury | 61.68 | 13.71 | 14 | 14258 | 300 | 70913872 |
Carotid arteriosclerosis | 58.49 | 13.71 | 21 | 14251 | 2406 | 70911766 |
Vascular anastomotic haemorrhage | 58.32 | 13.71 | 13 | 14259 | 256 | 70913916 |
Rectal prolapse | 58.25 | 13.71 | 20 | 14252 | 2009 | 70912163 |
Amyotrophic lateral sclerosis | 56.89 | 13.71 | 19 | 14253 | 1755 | 70912417 |
Abdominal wall haemorrhage | 56.43 | 13.71 | 15 | 14257 | 628 | 70913544 |
Muscle rupture | 54.90 | 13.71 | 22 | 14250 | 3403 | 70910769 |
Perineal cyst | 53.70 | 13.71 | 12 | 14260 | 239 | 70913933 |
Delayed graft function | 52.13 | 13.71 | 21 | 14251 | 3292 | 70910880 |
Alanine aminotransferase increased | 51.33 | 13.71 | 100 | 14172 | 147380 | 70766792 |
Aortic dilatation | 50.21 | 13.71 | 17 | 14255 | 1637 | 70912535 |
Actinic keratosis | 47.55 | 13.71 | 23 | 14249 | 5567 | 70908605 |
Vascular compression | 46.55 | 13.71 | 12 | 14260 | 445 | 70913727 |
Renal artery stenosis | 45.49 | 13.71 | 19 | 14253 | 3265 | 70910907 |
Myocardial infarction | 45.35 | 13.71 | 104 | 14168 | 171541 | 70742631 |
Aortic arteriosclerosis | 40.15 | 13.71 | 23 | 14249 | 7846 | 70906326 |
Coronary artery disease | 40.12 | 13.71 | 56 | 14216 | 62680 | 70851492 |
Diverticulum intestinal | 39.68 | 13.71 | 23 | 14249 | 8018 | 70906154 |
Hyperparathyroidism secondary | 39.51 | 13.71 | 16 | 14256 | 2542 | 70911630 |
Benign prostatic hyperplasia | 39.03 | 13.71 | 25 | 14247 | 10418 | 70903754 |
Mean cell volume increased | 38.52 | 13.71 | 20 | 14252 | 5624 | 70908548 |
Hepatosplenomegaly | 38.43 | 13.71 | 20 | 14252 | 5650 | 70908522 |
Intervertebral disc space narrowing | 35.79 | 13.71 | 13 | 14259 | 1539 | 70912633 |
Rheumatoid arthritis | 34.86 | 13.71 | 8 | 14264 | 291797 | 70622375 |
Toxicity to various agents | 32.88 | 13.71 | 18 | 14254 | 382154 | 70532018 |
Joint swelling | 32.19 | 13.71 | 6 | 14266 | 253205 | 70660967 |
Activated partial thromboplastin time prolonged | 31.01 | 13.71 | 24 | 14248 | 13481 | 70900691 |
Arteriosclerosis | 30.66 | 13.71 | 26 | 14246 | 16612 | 70897560 |
Blood 25-hydroxycholecalciferol decreased | 30.14 | 13.71 | 8 | 14264 | 333 | 70913839 |
Left ventricular hypertrophy | 29.90 | 13.71 | 21 | 14251 | 10181 | 70903991 |
Blood potassium increased | 29.88 | 13.71 | 32 | 14240 | 27294 | 70886878 |
Completed suicide | 29.70 | 13.71 | 5 | 14267 | 227130 | 70687042 |
Glycosylated haemoglobin increased | 29.66 | 13.71 | 26 | 14246 | 17365 | 70896807 |
Peripheral swelling | 29.24 | 13.71 | 6 | 14266 | 236557 | 70677615 |
Death | 29.07 | 13.71 | 36 | 14236 | 510025 | 70404147 |
Acute kidney injury | 28.57 | 13.71 | 178 | 14094 | 474446 | 70439726 |
Cerebrovascular accident | 28.48 | 13.71 | 78 | 14194 | 143392 | 70770780 |
Spinal osteoarthritis | 28.31 | 13.71 | 24 | 14248 | 15324 | 70898848 |
Muscular weakness | 28.25 | 13.71 | 76 | 14196 | 138260 | 70775912 |
Squamous cell carcinoma of skin | 27.91 | 13.71 | 22 | 14250 | 12690 | 70901482 |
Lactic acidosis | 27.52 | 13.71 | 48 | 14224 | 64976 | 70849196 |
Myoglobin blood increased | 27.32 | 13.71 | 13 | 14259 | 3034 | 70911138 |
Blood alkaline phosphatase increased | 27.14 | 13.71 | 45 | 14227 | 58476 | 70855696 |
Muscle spasms | 26.93 | 13.71 | 80 | 14192 | 153966 | 70760206 |
Complications of transplanted kidney | 26.73 | 13.71 | 16 | 14256 | 5918 | 70908254 |
Infusion related reaction | 26.61 | 13.71 | 4 | 14268 | 197530 | 70716642 |
Drug ineffective | 26.32 | 13.71 | 99 | 14173 | 939653 | 69974519 |
Haemorrhoids | 26.30 | 13.71 | 29 | 14243 | 25559 | 70888613 |
Fear | 25.68 | 13.71 | 26 | 14246 | 20785 | 70893387 |
Jaundice | 25.24 | 13.71 | 40 | 14232 | 50068 | 70864104 |
Spinal stenosis | 25.18 | 13.71 | 22 | 14250 | 14631 | 70899541 |
Vertigo | 24.91 | 13.71 | 45 | 14227 | 62598 | 70851574 |
Vestibular neuronitis | 24.63 | 13.71 | 8 | 14264 | 677 | 70913495 |
Swelling of eyelid | 24.36 | 13.71 | 12 | 14260 | 3020 | 70911152 |
Hyperkalaemia | 24.26 | 13.71 | 61 | 14211 | 106530 | 70807642 |
Tendon rupture | 23.82 | 13.71 | 19 | 14253 | 11150 | 70903022 |
Blood creatinine increased | 23.80 | 13.71 | 73 | 14199 | 142928 | 70771244 |
Face oedema | 22.86 | 13.71 | 27 | 14245 | 25612 | 70888560 |
General physical health deterioration | 22.80 | 13.71 | 101 | 14171 | 235930 | 70678242 |
Restless legs syndrome | 22.70 | 13.71 | 23 | 14249 | 18405 | 70895767 |
Myocardial ischaemia | 22.44 | 13.71 | 26 | 14246 | 24174 | 70889998 |
Product dose omission issue | 22.21 | 13.71 | 8 | 14264 | 217460 | 70696712 |
Hepatic steatosis | 21.33 | 13.71 | 30 | 14242 | 33783 | 70880389 |
Dysuria | 20.95 | 13.71 | 35 | 14237 | 45759 | 70868413 |
Blood urea increased | 20.88 | 13.71 | 35 | 14237 | 45874 | 70868298 |
Drug interaction | 19.85 | 13.71 | 138 | 14134 | 381303 | 70532869 |
Chromaturia | 19.71 | 13.71 | 24 | 14248 | 23504 | 70890668 |
Large intestine polyp | 19.25 | 13.71 | 17 | 14255 | 11459 | 70902713 |
Muscle necrosis | 19.23 | 13.71 | 8 | 14264 | 1360 | 70912812 |
Presyncope | 19.01 | 13.71 | 30 | 14242 | 37408 | 70876764 |
Product use in unapproved indication | 18.98 | 13.71 | 9 | 14263 | 207469 | 70706703 |
Renal cyst | 18.94 | 13.71 | 18 | 14254 | 13327 | 70900845 |
Hepatic function abnormal | 18.82 | 13.71 | 42 | 14230 | 67954 | 70846218 |
Aortic valve incompetence | 18.67 | 13.71 | 15 | 14257 | 8889 | 70905283 |
General physical condition | 18.38 | 13.71 | 3 | 14269 | 9 | 70914163 |
Product use issue | 17.73 | 13.71 | 7 | 14265 | 179930 | 70734242 |
Alopecia | 17.56 | 13.71 | 9 | 14263 | 198481 | 70715691 |
Angiosclerosis | 17.52 | 13.71 | 3 | 14269 | 13 | 70914159 |
Metabolic acidosis | 17.39 | 13.71 | 43 | 14229 | 74303 | 70839869 |
Vitamin D decreased | 17.26 | 13.71 | 14 | 14258 | 8413 | 70905759 |
Chronic kidney disease | 17.22 | 13.71 | 38 | 14234 | 61019 | 70853153 |
Atrioventricular block first degree | 17.05 | 13.71 | 16 | 14256 | 11657 | 70902515 |
Perioral dermatitis | 17.00 | 13.71 | 5 | 14267 | 304 | 70913868 |
Blood lactate dehydrogenase increased | 16.27 | 13.71 | 27 | 14245 | 35100 | 70879072 |
Pancreatitis acute | 16.11 | 13.71 | 31 | 14241 | 45193 | 70868979 |
Blood creatine phosphokinase MB | 16.06 | 13.71 | 3 | 14269 | 23 | 70914149 |
Immunosuppressant drug level increased | 15.90 | 13.71 | 13 | 14259 | 7894 | 70906278 |
Acute myocardial infarction | 15.84 | 13.71 | 41 | 14231 | 72846 | 70841326 |
Haematoma | 15.82 | 13.71 | 32 | 14240 | 48386 | 70865786 |
Interstitial lung disease | 15.19 | 13.71 | 51 | 14221 | 104634 | 70809538 |
Palmoplantar keratoderma | 15.16 | 13.71 | 5 | 14267 | 444 | 70913728 |
Febrile bone marrow aplasia | 14.83 | 13.71 | 15 | 14257 | 11976 | 70902196 |
Lipids abnormal | 13.94 | 13.71 | 5 | 14267 | 571 | 70913601 |
Congenital aortic dilatation | 13.71 | 13.71 | 3 | 14269 | 54 | 70914118 |
None
Source | Code | Description |
---|---|---|
ATC | C10AA04 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors |
FDA MoA | N0000000121 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
FDA EPC | N0000175589 | HMG-CoA Reductase Inhibitor |
CHEBI has role | CHEBI:35679 | antilipemic drugs |
CHEBI has role | CHEBI:77255 | lethal toxin inhibitors |
CHEBI has role | CHEBI:35821 | anticholesteremic drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypercholesterolemia | indication | 13644009 | |
Arteriosclerotic vascular disease | indication | 72092001 | |
Familial hypercholesterolemia - heterozygous | indication | 238079002 | |
Mixed hyperlipidemia | indication | 267434003 | |
Slow Progression of Coronary Artery Disease | indication | ||
Cerebrovascular accident | off-label use | 230690007 | |
Myocardial Infarction Prevention | off-label use | ||
Primary Prevention of Coronary Heart Disease | off-label use | ||
Prevention of Transient Ischemic Attacks | off-label use | ||
Alcoholism | contraindication | 7200002 | |
Low blood pressure | contraindication | 45007003 | |
Acute nephropathy | contraindication | 58574008 | |
Disorder of muscle | contraindication | 129565002 | DOID:423 |
Liver function tests abnormal | contraindication | 166603001 | |
Hemorrhagic cerebral infarction | contraindication | 230706003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Rhabdomyolysis | contraindication | 240131006 | |
Pregnancy, function | contraindication | 289908002 | |
Surgical procedure | contraindication | 387713003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Traumatic injury | contraindication | 417746004 | |
Uncontrolled Epilepsy | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.05 | acidic |
pKa2 | 13.34 | acidic |
pKa3 | 13.99 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Enzyme | INHIBITOR | IC50 | 7.55 | CHEMBL | DRUG LABEL | |||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.40 | DRUG MATRIX | |||||
Retinoic acid receptor RXR-alpha | Nuclear hormone receptor | Kd | 4.96 | CHEMBL | |||||
Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | WOMBAT-PK | |||||||
Sodium/bile acid cotransporter | Transporter | IC50 | 4.40 | CHEMBL | |||||
NAD-dependent protein deacetylase sirtuin-6 | Unclassified | EC50 | 5.15 | CHEMBL | |||||
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Enzyme | IC50 | 8.60 | CHEMBL |
ID | Source |
---|---|
D00892 | KEGG_DRUG |
93957-55-2 | SECONDARY_CAS_RN |
4020854 | VANDF |
4023909 | VANDF |
C0082608 | UMLSCUI |
CHEBI:38561 | CHEBI |
115 | PDB_CHEM_ID |
CHEMBL2220442 | ChEMBL_ID |
CHEMBL1078 | ChEMBL_ID |
CHEMBL2218894 | ChEMBL_ID |
D000077340 | MESH_DESCRIPTOR_UI |
DB01095 | DRUGBANK_ID |
23663976 | PUBCHEM_CID |
2951 | IUPHAR_LIGAND_ID |
6547 | INN_ID |
4L066368AS | UNII |
151972 | RXNORM |
1724 | MMSL |
189348 | MMSL |
4757 | MMSL |
d03183 | MMSL |
004439 | NDDF |
004440 | NDDF |
387585004 | SNOMEDCT_US |
412392009 | SNOMEDCT_US |
96307003 | SNOMEDCT_US |
CHEMBL103585 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
LescolXL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0354 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 30 sections |
LescolXL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0354 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 30 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7442 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7442 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7443 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7443 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7446 | TABLET, FILM COATED, EXTENDED RELEASE | 80 mg | ORAL | ANDA | 28 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7446 | TABLET, FILM COATED, EXTENDED RELEASE | 80 mg | ORAL | ANDA | 28 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8020 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8021 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2580 | TABLET, FILM COATED, EXTENDED RELEASE | 80 mg | ORAL | ANDA | 30 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2580 | TABLET, FILM COATED, EXTENDED RELEASE | 80 mg | ORAL | ANDA | 30 sections |
FLUVASTATIN SODIUMER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-8017 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA authorized generic | 27 sections |
LESCOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3329 | CAPSULE | 20 mg | ORAL | NDA | 15 sections |
LESCOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4224 | CAPSULE | 40 mg | ORAL | NDA | 15 sections |
LESCOL XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4601 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 15 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8737 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8737 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8812 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8812 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1326 | CAPSULE | 20 mg | ORAL | ANDA | 25 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1334 | CAPSULE | 40 mg | ORAL | ANDA | 25 sections |
Lescol XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-4471 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 26 sections |